comparemela.com

Latest Breaking News On - Toxicology study - Page 1 : comparemela.com

Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder

Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). In November, Silo Pharma announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15. The study aims to identify the maximum tolerated intranasal dose of th

Eric weisblumSilo pharma incSilo pharmaMedspray pharmaChief executive officerInvestigational new drugStock market gameBenzinga proDay trialSilo pharma concludes first phasePharmacokinetic studyDose ranging studyToxicology studyTherapeutic drug

Form S-1/A Scilex Holding Co

Form S-1/A Scilex Holding Co
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDistrict of columbiaNorth dakotaSan diegoStanford universityNew yorkSouth africaCayman islandsEteläuomen läiPalo altoHong kongSan francisco bayMonte carloTel avivUnited kingdomState of california

Benitec Biopharma Inc : Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic

United statesWilliam windhamClinical development program overviewBenitec or companyBenitec biopharma incSolebury strategic communicationsExchange commissionRegulatory updates for the clinical development programResearch ethics boardAssay method developmentSecond fiscal quarterExecutive chairmanChief executive officerOculopharyngeal muscular dystrophyDevelopment program overviewTreatment evaluation

Curative Biotechnology, Inc ?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare

Paul michaelsSteve chizzikBoca ratonDevelopment agreementSecurities exchangeCurative biotechnology incInvestigational new drugToxicology studyTopical instillationCurative biotechnologyIntermediate dry age related macular degenerationGeographical atrophyCooperative researchNational eye instituteNational institutesBethesda maryland

Theralase® Closes $2 5M Private Placement Equity Financing

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage.

United statesKristina hacheyYork stock exchangeCompany photo dynamic compoundsGood laboratory practiceToronto stock exchangeAmerican stock exchangeTechnologies incNew york stock exchangeParty transactionsCompany common shareVenture exchangeRegulation services providerPhoto dynamic compoundsEach warrantCommon share

vimarsana © 2020. All Rights Reserved.